A little more than five months after Pfizer discontinued development of its weight-loss drug known as danuglipron, the drugmaker announced its plan on Monday to acquire a biopharmaceutical company for close to $5 billion.

Pfizer published a press release on Monday confirming the unanimous agreement to acquire Metsera, a "clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and cardiometabolic diseases."

'Obesity is a large and growing space with over 200 health conditions associated with it.'

According to the terms of the agreement, Pfizer will acquire all outstanding shares of Metsera common stock for $47.50 per share in cash at closing, representing an enterprise value of approximately $4.9 billion.

While Pfizer reportedly does no

See Full Page